CVS Health Corp
CVS
ISIN US1266501006 / Valor 548525
CVS Health Corp
UMushroom community rating:
About company
CVS Health Corp is a leading healthcare company that offers a wide range of services, including pharmacy benefits management, retail pharmacy, and healthcare clinics. The company has expanded its business through strategic acquisitions, such as Coram, Omnicare, Navarro Discount Pharmacy, and Target's pharmacies and clinics. In response to the COVID-19 pandemic, CVS has played a significant role in providing testing and vaccinations, partnering with the CDC to offer on-site vaccinations at nursing homes and assisted living facilities.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.08.2024):
Total Revenue Growth
In the fourth quarter of 2023, CVS Health Corp's total revenues increased to $93.8 billion, marking an 11.9% rise compared to the same period in the previous year. This growth was driven by strong performance across all segments of the company.
Adjusted Earnings Per Share
For the fourth quarter of 2023, CVS Health Corp reported an adjusted earnings per share (EPS) of $2.12, which is an increase from the $2.04 adjusted EPS reported in the fourth quarter of 2022. This reflects a positive adjustment in the company's earnings performance.
Full-Year Revenue
For the full year ending December 31, 2023, CVS Health Corp's total revenues reached $357.8 billion, representing a 10.9% increase compared to the previous year. This substantial growth underscores the company's robust financial health and operational success over the year.
Dividend Increase
CVS Health Corp announced a 10% increase in its quarterly shareholder dividend, which took effect with the February 1, 2024 dividend distribution. In 2023, the company returned $3.1 billion to shareholders through dividends, highlighting its commitment to delivering value to its investors.
2024 Financial Guidance
Looking ahead, CVS Health Corp has revised its 2024 full-year guidance. The company now expects GAAP diluted EPS to be at least $7.06, down from the previous guidance of at least $7.26. Adjusted EPS guidance has also been revised to at least $8.30 from the earlier forecast of at least $8.50, reflecting anticipated challenges in the upcoming year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
73491 M
Market cap (USD)
1,252,300
Daily traded volume (Shares)
59.18 / 57.82
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
